Skip to main content
Caplight Logo









Prota Therapeutics

Prota Therapeutics

Private
MelbourneHealthcare & Life Scienceshttps://protatherapeutics.com/

Last Round

Series A

Extension

Jan 16, 2024

Total Funding Raised

$43.48M

Company Overview

Prota Therapeutics is a biotechnology company that develops and commercializes oral immunotherapy treatments for food allergies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oral immunotherapypeanut allergy treatmentOITfood allergy therapypediatric biotechnologyclinical-stage biotechallergy desensitizationclinical trialsdrug developmentbiotech startupallergy cure research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Prota Therapeutics Comparables

Compare Prota Therapeutics with similar companies based on industry and business-model similarity.

Prota Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aravax
87%
Intrommune Therapeutics
84%
Camallergy
83%

Prota Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 16, 2024
Series AMay 27, 2017
Series ASep 1, 2016

Key People

Founding team and executive leadership

Mark Hasleton

Acting Chief Executive Officer

Executive Team

Prota Therapeutics Investors

Notable investors and investment history

Prota Therapeutics investors
InvestorRounds
OneVenturesSeries A Extension, Series A
SPRIM Global InvestmentsSeries A Extension
SPRIM Global InvestmentsSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 17, 2025

    Investigational peanut allergy therapy PRT120 mentioned in award announcement.

  • Sep 17, 2025

    Awarded for joint clinical research with Murdoch Children's Research Institute.

Prota Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Prota Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Prota Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMelbourne
Employee Range5
Year Founded2016
Last FundingJan 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.